Role of Bim in mediating CAM-DR in hematopoietic tumors
Bim 在介导造血肿瘤 CAM-DR 中的作用
基本信息
- 批准号:7482486
- 负责人:
- 金额:$ 28.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-08-08 至 2012-05-31
- 项目状态:已结题
- 来源:
- 关键词:Acute Myelocytic LeukemiaAdhesionsApoptosisBindingBiological ModelsBone MarrowCell AdhesionCell DeathCell SurvivalCellsCessation of lifeChronic Myeloid LeukemiaClinicalCoculture TechniquesCultured CellsDataDisruptionDoctor of PhilosophyDrug resistanceEngraftmentEventExtracellular MatrixFailureFibronectinsGoalsGrantGrowth FactorHematopoietic NeoplasmsHomingHumanIn VitroIntegrinsMSX1 geneMediatingMelphalanModelingMulti-Drug ResistanceMultiple MyelomaMyeloid LeukemiaPathway interactionsPatientsPeptidesPharmaceutical PreparationsPhenotypePhosphorylationPost-Translational RegulationRegulationRelative (related person)Research PersonnelResidual NeoplasmResistanceRoleSignal TransductionSmall Interfering RNASpecimenStandards of Weights and MeasuresSuspension substanceSuspensionsTestingWorkbonechemotherapycytokinecytotoxicdrug efficacyin vivo Modelintegrin-linked kinasekillingsleukemialorisneoplastic cellpreventprogramsresponsesmall hairpin RNAsrc-Family Kinasessuccesstooltraffickingtumorvector
项目摘要
DESCRIPTION (provided by applicant): Failure to eliminate minimal residual disease (MRD) continues to limit the success of chemotherapy in multiple myeloma (MM), acute myeloid leukemia (AML) and chronic myelogenous leukemia (CML). We propose the tumor microenvironment consists of specialized niches that contribute to de-novo resistance and ultimately to the failure to eliminate minimal (MRD) in hematopoietic tumors. One microenvironment that is particularly relevant to hematopoietic tumors is the bone marrow. The bone marrow microenvironment supports high local concentrations of cytokines, growth factors and components of extracellular matrixes. We previously showed that cell adhesion via beta 1 integrins to FN is sufficient to protect leukemic and MM cells from drug-induced apoptosis. We have referred to this phenotype as cell adhesion mediated drug resistance or CAM-DR. This proposal will investigate the role of Bim in mediating the CAM-DR phenotype. In addition, this proposal will delineate pathways and targets that are causative for reduced Bim levels in adhered cells. Finally, we will determine whether targeting beta 1 integrin mediated signaling increases the efficacy of chemotherapy in a bone marrow stroma and SCID-Hu model of drug resistance. To this end specific aim 1 of this grant will determine the overall contribution of reduced Bim levels in mediating the CAM-DR phenotype. Specific aim 2 of this grant will determine whether post-translational regulation of Bim is causally related to reduced Bim levels in adherent cells. In specific aim 3 of this proposal we will disrupt beta 1 integrin mediated signaling and determine whether this results in increased cell death induced by chemotherapy in a bone marrow stroma co-culture model and the SCID-Hu in vivo model. In summary, we hypothesize that cell adhesion mediated reduction in Bim levels is a critical determinant of CAM-DR and contributes to the failure of currently used cytotoxics to eliminate MRD in hematopoietic tumors. This hypothesis will be rigorously tested in this proposal. Relevance: The failure to eliminate minimal residual disease associated with hematopoietic tumors impedes the success of standard chemotherapy. In this proposal we will test whether disrupting beta 1 integrin mediated signaling increases the potency of standard chemotherapy in the bone marrow microenvironment.
描述(由申请人提供):未能消除最小残留疾病(MRD)继续限制多发性骨髓瘤(MM),急性骨髓性白血病(AML)和慢性脊髓性白血病(CML)中化学疗法的成功。我们提出的肿瘤微环境由有助于脱诺沃耐药性的专业生态市场组成,并最终导致无法消除造血肿瘤中最小的(MRD)。骨髓是一种与造血肿瘤特别相关的微环境。骨髓微环境支持局部浓度高的细胞因子,生长因子和细胞外基质的成分。我们先前表明,通过β1整合素对FN的细胞粘附足以保护白血病和MM细胞免受药物诱导的凋亡的影响。我们将这种表型称为细胞粘附介导的耐药性或CAM-DR。该建议将研究BIM在介导CAM-DR表型中的作用。此外,该建议将描述途径和目标,这些途径和目标是粘附细胞中BIM水平降低的途径。最后,我们将确定靶向β1整合素介导的信号传导是否会增加化学疗法在骨髓基质和耐药性模型中的疗效。为此,该赠款的特定目的1将决定降低BIM水平在介导CAM-DR表型中的总体贡献。该赠款的具体目的2将确定BIM的翻译后调节是否与粘附细胞中BIM水平降低有关。在该提案的特定目的3中,我们将破坏β1整合素介导的信号传导,并确定这是否导致骨髓基质共培养模型中化学疗法诱导的细胞死亡增加和体内模型的SCID-HU。总而言之,我们假设细胞粘附介导的BIM水平降低是CAM-DR的关键决定因素,并有助于当前使用的细胞毒剂消除造血肿瘤中MRD的失败。该假设将在此提案中进行严格检验。相关性:未能消除与造血肿瘤相关的最小残留疾病会阻碍标准化疗的成功。在此提案中,我们将测试破坏β1整合素介导的信号传导是否会增加骨髓微环境中标准化疗的效力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lori A Hazlehurst其他文献
Lori A Hazlehurst的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lori A Hazlehurst', 18)}}的其他基金
Specific skeletal targeting of MMP-2 for the treatment of multiple myeloma
MMP-2 的特异性骨骼靶向治疗多发性骨髓瘤
- 批准号:
8959015 - 财政年份:2015
- 资助金额:
$ 28.39万 - 项目类别:
Targeting CD44-mediated calcium signaling for the treatment of relapsed myeloma
靶向 CD44 介导的钙信号传导治疗复发性骨髓瘤
- 批准号:
9135272 - 财政年份:2015
- 资助金额:
$ 28.39万 - 项目类别:
Specific skeletal targeting of MMP-2 for the treatment of multiple myeloma
MMP-2 的特异性骨骼靶向治疗多发性骨髓瘤
- 批准号:
9104117 - 财政年份:2015
- 资助金额:
$ 28.39万 - 项目类别:
Targeting CD44-mediated calcium signaling for the treatment of relapsed myeloma
靶向 CD44 介导的钙信号传导治疗复发性骨髓瘤
- 批准号:
8899958 - 财政年份:2015
- 资助金额:
$ 28.39万 - 项目类别:
Targeting CD44-mediated calcium signaling for the treatment of relapsed myeloma
靶向 CD44 介导的钙信号传导治疗复发性骨髓瘤
- 批准号:
9763481 - 财政年份:2015
- 资助金额:
$ 28.39万 - 项目类别:
Targeting CD44 in the bone marrow microenvironment of MM
靶向 MM 骨髓微环境中的 CD44
- 批准号:
8453303 - 财政年份:2012
- 资助金额:
$ 28.39万 - 项目类别:
Chemical Optimization Designed to Increase the in vivo Efficacy of HM-27 for the
旨在提高 HM-27 体内功效的化学优化
- 批准号:
8395611 - 财政年份:2012
- 资助金额:
$ 28.39万 - 项目类别:
Role of Bim in mediating CAM-DR in hematopoietic tumors
Bim 在介导造血肿瘤 CAM-DR 中的作用
- 批准号:
8072555 - 财政年份:2007
- 资助金额:
$ 28.39万 - 项目类别:
Role of Bim in mediating CAM-DR in hematopoietic tumors
Bim 在介导造血肿瘤 CAM-DR 中的作用
- 批准号:
7837605 - 财政年份:2007
- 资助金额:
$ 28.39万 - 项目类别:
Role of Bim in mediating CAM-DR in hematopoietic tumors
Bim 在介导造血肿瘤 CAM-DR 中的作用
- 批准号:
7314522 - 财政年份:2007
- 资助金额:
$ 28.39万 - 项目类别:
相似国自然基金
促细胞外囊泡分泌的绒毛膜纳米纤维仿生培养体系的构建及其在宫腔粘连修复中的应用研究
- 批准号:32301204
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
载Pexidartinib的纳米纤维膜通过阻断CSF-1/CSF-1R通路抑制巨噬细胞活性预防心脏术后粘连的研究
- 批准号:82370515
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
泛素连接酶SMURF2通过SMAD6-COL5A2轴调控宫腔粘连纤维化的分子机制研究
- 批准号:82360301
- 批准年份:2023
- 资助金额:31 万元
- 项目类别:地区科学基金项目
负载羟基喜树碱的双层静电纺纳米纤维膜抑制肌腱粘连组织增生的作用和相关机制研究
- 批准号:82302691
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
活血通腑方调控NETs干预术后腹腔粘连组织纤维化新途径研究
- 批准号:82374466
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
相似海外基金
Investigating the mechanism of SHP2 and BCL2 Inhibition in Acute Myeloid Leukemia (AML)
研究急性髓系白血病 (AML) 中 SHP2 和 BCL2 抑制的机制
- 批准号:
10736325 - 财政年份:2023
- 资助金额:
$ 28.39万 - 项目类别:
Leukemia stem cell polarity and differentiation therapy
白血病干细胞极性与分化治疗
- 批准号:
10227111 - 财政年份:2017
- 资助金额:
$ 28.39万 - 项目类别:
Exosomal MicroRNA as a Driver of Immune Evasion in AML
外泌体 MicroRNA 作为 AML 免疫逃避的驱动因素
- 批准号:
8997997 - 财政年份:2014
- 资助金额:
$ 28.39万 - 项目类别:
Exosomal MicroRNA as a Driver of Immune Evasion in AML
外泌体 MicroRNA 作为 AML 免疫逃避的驱动因素
- 批准号:
8793686 - 财政年份:2014
- 资助金额:
$ 28.39万 - 项目类别: